Hong-Chuang Xu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/484578/publications.pdf

Version: 2024-02-01

9	124	7	9
papers	citations	h-index	g-index
9	9	9	190
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Platinum(II)-Based Convex Trigonal-Prismatic Cages via Coordination-Driven Self-Assembly and C ₆₀ Encapsulation. Inorganic Chemistry, 2017, 56, 12498-12504.	4.0	26
2	2,7-naphthyridinone-based MET kinase inhibitors: A promising novel scaffold for antitumor drug development. European Journal of Medicinal Chemistry, 2019, 178, 705-714.	5.5	24
3	Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation. Journal of Medicinal Chemistry, 2021, 64, 15503-15514.	6.4	22
4	Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2. Bioorganic and Medicinal Chemistry, 2020, 28, 115555.	3.0	13
5	Ultrafast 2,7-Naphthyridine-Based fluorescent probe for detection of thiophenol with a remarkable Stokes shift and its application In vitro and in vivo. Talanta, 2019, 205, 120067.	5.5	12
6	Efficient Arylation of 2,7-Naphthyridin-1 (2H)-one with Diaryliodonium Salts and Discovery of a New Selective MET/AXL Kinase Inhibitor. ACS Combinatorial Science, 2020, 22, 457-467.	3.8	11
7	Structure–activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy. European Journal of Medicinal Chemistry, 2020, 208, 112785.	5.5	7
8	Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology. Topics in Current Chemistry, 2021, 379, 23.	5.8	6
9	Conformational adjustment overcomes multiple drug-resistance mutants of tropomyosin receptor kinase. European Journal of Medicinal Chemistry, 2022, 237, 114406.	5.5	3